ADPT — Adaptive Biotechnologies Corp

Nasdaq · Health Care · Biotechnology · CIK 1478320 ·
Last close
$17.60
Market Cap
$2.82B
52W High
$19.52
52W Low
$12.02
ADV30
2,132,420
Next earnings
2026-08-04
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 70,874,000 52,166,000 -19,206,000 -20,033,000 505,943,000 77,581,000 281,702,000
Dec 2025 71,681,000 53,457,000 -12,773,000 -13,579,000 512,736,000 70,495,000 287,735,000
Sep 2025 93,973,000 75,816,000 10,290,000 9,546,000 490,610,000 55,034,000 286,357,000
Jun 2025 58,879,000 40,880,000 -25,036,000 -25,614,000 496,637,000 43,163,000 317,101,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-45,986,000
Investing CF
$37,950,000
Financing CF
$30,403,000
CapEx
$-2,959,000
Dividends Paid
Buybacks
EPS Diluted TTM
$-0.40
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,363,323,000
Inventory
$9,820,000
Receivables
$50,365,000
ST Investments
$156,485,000
EBIT TTM
$-47,679,000
Pretax Income TTM
$-59,457,000
Interest Exp TTM
$11,778,000
Analysts
7

Yahoo Snapshot (yfinance, live)

Total Revenue
$295,407,008
EBITDA
$-29,786,000
Free Cash Flow
$16,102,625
Enterprise Value
$2,814,529,280
Total Cash
$218,334,000
Total Debt
$208,180,992
Shares Out
160,044,392
Trailing EPS
$-0.32
Book Value
$1.35
ROE
-24.0%
ROA
-5.7%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 276,976,000 -57,123,000 -59,499,000 512,736,000 287,735,000 -45,986,000
Dec 2024 178,957,000 -155,344,000 -159,492,000 539,376,000 336,891,000 -95,212,000
Dec 2023 170,276,000 -201,606,000 -225,250,000 661,134,000 352,856,000 -156,324,000
Dec 2022 185,308,000 -200,186,000 -200,191,000 856,617,000 392,519,000 -183,945,000

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$-0.25

Max Pain — expiry 2026-07-17 (volume-derived — Yahoo OI feed degraded)

max pain strike: $17.50 · spot: $17.46 · call volume: 143 · put volume: 32
Expected Move to 2026-07-17: ±$3.88 (22.19%) — implied range $13.58$21.33 · ATM straddle on $17.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
TARS Tarsus Pharmaceuticals, Inc. $2.67B $61.95
BEAM Beam Therapeutics Inc. $2.99B $29.03
RLAY Relay Therapeutics, Inc. $3.23B $14.81
DNLI Denali Therapeutics Inc. $3.44B $21.66
BCRX BIOCRYST PHARMACEUTICALS INC $2.21B $8.70

News headlines (Yahoo Finance, 1h cache)

Adaptive Biotechnologies Announces Plan to Separate Its MRD and Immune Medicine Businesses
2026-06-15 20:10 · Yahoo
Adaptive Biotechnologies Corporation Announces Proposed Convertible Senior Notes Offering
2026-06-15 20:05 · Yahoo
What Does an Adaptive Biotech Insider's Sale of Nearly 40,000 Shares Mean for Investors?
2026-06-14 22:46 · Yahoo
Adaptive Biotechnologies (ADPT) Moves 9.7% Higher: Will This Strength Last?
2026-06-12 09:44 · Yahoo
OpenFold Consortium Adds Eleven New Members as Momentum Builds for Open AI Infrastructure in Biology and Drug Discovery
2026-06-09 13:00 · Yahoo
How The Adaptive Biotechnologies (ADPT) Narrative Is Shifting Around A US$20 Fair Value Anchor
2026-06-04 11:10 · Yahoo
Adaptive Biotechnologies Highlights clonoSEQ Growth, 2026 Cash Flow Goal at Conference
2026-06-03 22:04 · Yahoo
Adaptive Biotech (ADPT) Reports 35% Revenue Growth Driven by Strong clonoSEQ Performance in Q1 2026
2026-06-03 18:00 · Yahoo
At ASCO and EHA 2026, New Data Reinforce the Pivotal Role of clonoSEQ® MRD Testing Across Hematology Clinical Practice and Research
2026-05-29 11:30 · Yahoo
Harvest Investment Services Dumps 356,000 Adaptive Biotechnologies (ADPT) Shares Worth $5.7 Million
2026-05-26 20:23 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.